ValuentumAd

Official PayPal Seal

Johnson & Johnson Remains an Innovation Powerhouse

publication date: Jun 21, 2025
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Image Source: Johnson & Johnson. 

J&J generated free cash flow of ~$3.4 billion in the first quarter compared to $2.85 billion in the year-ago period. Looking to full year 2025 guidance, J&J reiterated its adjusted operational sales growth target in the range of 2%-3%, but it raised its operational sales growth expectations to the range of 3.3%-4.3% from 2.5%-3.5% previously and its estimated reported sales growth guidance to the range of 2.6%-3.6% from 0.5%-1.5% previously. It lowered its adjusted operational earnings per share guidance for the year, but it maintained its adjusted diluted earnings per share guidance in the range of $10.50-$10.70, reflecting 6.2% growth at the midpoint. Shares yield 3.5% at the time of this writing.


Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.